The pharmaceutical industry has been actively seeking the ideal treatment for hepatitis C for years: a treatment whose features would be an eradication of the virus from the body in 100% of cases.
In 2013, an innovative neurology is emerging which is overcoming all kinds of hurdles: genetics, biotechnology, medical imaging, neurosurgery, the pharmaceutical industry… fundamental and clinical research are uniting
In December 2013 the Critical Illness Defi nitions and Geographical Variations Working Party presented their paper, ‘Extending the Critical Path’ to the Staple Inn Actuarial Society.
Winner of the Actuarial Award in Asia, 2013
In 2013, an innovative neurology is emerging which is overcoming all kinds of hurdles: genetics, biotechnology, medical imaging, neurosurgery, the pharmaceutical industry… fundamental and clinical research are uniting
In 2013, an innovative neurology is emerging which is overcoming all kinds of hurdles: genetics, biotechnology, medical imaging, neurosurgery, the pharmaceutical industry… fundamental and clinical research are uniting
In 2013, an innovative neurology is emerging which is overcoming all kinds of hurdles: genetics, biotechnology, medical imaging, neurosurgery, the pharmaceutical industry… fundamental and clinical research are uniting
In 2013, an innovative neurology is emerging which is overcoming all kinds of hurdles: genetics, biotechnology, medical imaging, neurosurgery, the pharmaceutical industry… fundamental and clinical research are uniting
SCOR Global Life, a subsidiary of SCOR SE, has entered into a VIF (Value of In-Force) monetization transaction with Mediterráneo Vida, a Spanish insurance company fully owned by Banco Sabadell.
Marie-Laurence Bouchon has joined SCOR as Head of Group Communications. Based in Paris, she is responsible for coordinating all facets of Group communication, both external and internal.
SCOR Global Life, a subsidiary of SCOR SE, has entered into a longevity transaction with the UK-based insurer Aviva.
SCOR Global Life, a subsidiary of SCOR SE, has entered into a longevity transaction with the UK-based insurer Aviva.
